Novo Nordisk raises full-year guidance again on GLP-1 sales
The Danish drugmaker now expects sales and operating profit to decline by no more than 6% at constant exchange rates, yet shares slipped.
TR
By Tom Reyes · Markets Editor
Aug 4 03:00 ETSource: seekingalpha.com
The wire
- 01Novo Nordisk lifted its full-year outlook for the second time this year, citing higher expected GLP-1 product sales, and now guides to a decline of no more than 6% at constant exchange rates.
- 02Novo's incretin demand and revenue trajectory drive semaglutide supply and pricing decisions that pharmacists and telehealth prescribers work around.
- 03Shares still fell on the update; the item does not break out Wegovy or Ozempic figures or explain the market's negative reaction.
From the source
Read at seekingalpha.comNovo Nordisk slips despite lifting guidance on GLP-1 strength (NVO:NYSE)
Novo Nordisk ( NVO ) raised its full-year outlook for the second time this year, citing increased expectations for GLP-1 product sales.
